Smart sensors aim to monitor muscle weakness in real time

NCT ID NCT07226830

Not yet recruiting Knowledge-focused Sponsor: BioSensics Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 03, 2026 · Updated 26 times

Summary

This study looks at whether wearable devices and smartphone apps can effectively track disease activity in people with generalized myasthenia gravis (gMG) who are starting treatment with VYVGART or VYVGART Hytrulo. Twenty-five participants will wear sensors to measure physical activity, speech, and other symptoms over 16 weeks. The goal is to see if digital tools can provide a clearer picture of how the disease changes during treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital, Neuromuscular Diagnostic Center

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.